X

Trial Profile

A Phase 2 Clinical Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

02 Jul 2020 Status changed from recruiting to completed, according results published in the Journal of Clinical Oncology
02 Jul 2020 Results published in the Journal of Clinical Oncology
04 Jun 2019 Results (n=20; as of 10 Dec 2018) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com